RXRX
Recursion Pharmaceuticals (RXRX) Stock Valuation
Review Recursion Pharmaceuticals (RXRX) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 0
- Price to book
- 1.88
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- $237.87M
- Premium or discount
- 646.24%
- Market cap
- $1.78B
Recursion Pharmaceuticals (RXRX) Stock Valuation research
The Recursion Pharmaceuticals valuation page presents the available multiples, profitability measures and BTI fair-value context for RXRX. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.